Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. - Wikidata - awgldk - TriplyDB

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.

http://www.wikidata.org/entity/Q33345317

about

Multiple myeloma Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma The role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy Novel strategies to target the ubiquitin proteasome system in multiple myeloma Novel agents for multiple myeloma to overcome resistance in phase III clinical trials Ethanol-induced oxidant stress modulates hepatic autophagy and proteasome activity Targeting the ubiquitin-proteasome system in heart disease: the basis for new therapeutic strategies Systematic approaches to identify E3 ligase substrates Trial Watch: Proteasomal inhibitors for anticancer therapy Proteasome inhibitors disrupt the unfolded protein response in myeloma cells Proteasomal non-catalytic subunit PSMD2 as a potential therapeutic target in association with various clinicopathologic features in lung adenocarcinomas Regulation of proteasome activity in health and disease From bench to bedside: lessons learned in translating preclinical studies in cancer drug development Variation in drug sensitivity of malignant mesothelioma cell lines with substantial effects of selenite and bortezomib, highlights need for individualized therapy Galectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myeloma The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders.Management of multiple myeloma with bortezomib: experts review the data and debate the issues.Transglutaminase 2 mediates polymer formation of I-kappaBalpha through C-terminal glutamine cluster.Bortezomib is an efficient agent in plasma cell leukemias.Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.A pilot study of bortezomib in Korean patients with relapsed or refractory myeloma Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207.Bortezomib (Velcadetrade mark) in the Treatment of Multiple Myeloma Targeting the UPS as therapy in multiple myeloma.Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma.Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG).Carfilzomib: a novel second-generation proteasome inhibitor Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study.Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes.Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib Proteasome inhibitors and cardiac cell growth A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia.Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board.Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells.Targeting the ubiquitin-proteasome pathway with inorganic compounds to fight cancer: a challenge for the future.Proteasome functional insufficiency activates the calcineurin-NFAT pathway in cardiomyocytes and promotes maladaptive remodelling of stressed mouse hearts.Proteasome inhibition and its therapeutic potential in multiple myeloma Bortezomib in the management of multiple myeloma.

P2860

Q24655964-1661B1AF-AB8F-4B2D-A0C6-D60B0AA47249 Q24669938-B40A42DF-548C-4CDA-A760-7001A7A60DB3 Q24794927-B022CB6E-4883-452A-B6A1-570EFC37ED51 Q24814325-A90BFF2B-19BB-42C0-9E85-1D4A03B7199A Q26773246-521CCF76-68B8-4174-B736-015D6FBC6644 Q26822754-5D6F2456-23F3-4168-AB28-6893A829BC11 Q26852284-6F461D69-20E6-484C-B2BE-512C2C71452A Q27026951-E5E46F80-895F-4146-B51A-946F24E636AB Q28068398-06BD95DB-743F-4690-901D-E400C5426D04 Q28082910-C1262BD7-648F-418A-9024-FE87EC56F26C Q28155919-92A896BE-6CEF-4EE9-A369-449B7FCCEEF8 Q28308220-30060D4D-BCE5-4FB1-9A04-3C6ECB66134D Q28392708-698AB5CC-CDF1-4723-B887-25F7D9591235 Q28533949-C2B301E4-4564-42F2-AA4F-870519D2D65D Q28534042-3F27FD8B-C44F-407F-924D-2622442C9986 Q28742668-CE4780AA-B0DC-41E4-BFE9-AA13099746F8 Q30248842-CACE0109-57F0-44DD-A4C7-6F7DB3BEC723 Q31098282-A2A2F1AD-E6D8-4A1B-9F1D-607CBD80CA8E Q33258202-C6312A95-2A36-4F3E-8DC2-251E09197BC6 Q33364213-6C0ED73C-0474-4D82-B580-76D7BD758AA3 Q33367821-8E1AC86F-A2A5-49B7-9A04-D208799BFE32 Q33367833-719F03F5-017F-48DA-8E09-CE8D06396D88 Q33378628-F268819C-D85C-45D0-BFA7-846474EDC9DF Q33379044-AC53B494-28E6-42C6-9DA8-496EADBA472F Q33384287-58437C69-FC6B-4607-B124-7A9672676974 Q33388541-B116EBCE-E8A7-406A-A481-EC7B46F7F67D Q33391725-7AC6401E-C6ED-4266-AFE2-14C49B8F6DC0 Q33395298-49DEC347-580B-4E47-9771-FEF4A3C4136D Q33404090-95C7B5CE-BA5F-4312-B8CF-33E556032CC7 Q33409172-5A019628-F647-409C-9BE2-A408545EBE1B Q33425190-36862805-9070-4F3F-ACBE-E7FAF3496A40 Q33554490-E4E3D8D8-4E22-43A1-AC9C-0E420DF39130 Q33630851-A498911C-F791-4230-AE59-6BBE9DEC131E Q33632270-B159B565-77E4-44A4-A570-EA17950C4A40 Q33703096-DC2EA573-3289-4D76-B8D7-584BFEDF8738 Q33747277-4E18063A-E89E-4BFF-A9E3-AF5FFAB1CF92 Q34195083-BF8135E9-640B-428A-9C2A-DF619A79CF87 Q34275603-E22A9BF5-272A-447E-A822-3C5239D65C37 Q34343036-D678FD01-4DDB-4B25-8F27-5CF010B70EE2 Q34418462-07300F9A-F916-4D49-A4D2-46C92B4D9AE7

P2860

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.

http://www.wikidata.org/entity/Q33345317

description

2002 nî lūn-bûn

@nan

2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Phase I trial of the proteasom ...... tory hematologic malignancies.

@ast

Phase I trial of the proteasom ...... tory hematologic malignancies.

@en

type

label

Phase I trial of the proteasom ...... tory hematologic malignancies.

@ast

Phase I trial of the proteasom ...... tory hematologic malignancies.

@en

prefLabel

Phase I trial of the proteasom ...... tory hematologic malignancies.

@ast

Phase I trial of the proteasom ...... tory hematologic malignancies.

@en

P1433

Q33345317-43E58D28-F8AA-44EF-BD3A-ABA8F3E3CD8E

P1476

Q33345317-66C52F13-1405-4218-9B52-88B8E405C47F

P2093

Q33345317-091A5F0E-1E31-443D-8F67-A35672B69F69

Q33345317-0FAE1600-B287-481D-B157-E244CEE1F1AD

Q33345317-23F31697-D739-48D4-A8DE-84D7F854936A

Q33345317-3ADDEF9C-5352-4A7A-A229-B1CB35FB8FA9

Q33345317-40AFFE93-381B-4773-96BB-28B740FD062A

Q33345317-45A5240E-3650-4590-9755-C46921C9B010

Q33345317-8571D546-96BE-428C-AE91-37AB91B04E3B

Q33345317-8735D6DA-14EB-4F82-8857-5F02402C03E1

Q33345317-9210878E-232D-49D3-A1C5-B457AA2C1109

Q33345317-92467471-3ADC-4FF3-B769-91520E906FE9

P304

Q33345317-7D4FB9F7-500E-47B6-84B1-E1D03376807F

P31

Q33345317-567A4F86-3499-4A8B-A0FF-9769D751BB7A

P356

Q33345317-8D6FFF6E-E9F8-4178-93CB-D5FB6AE4AE78

P407

Q33345317-48FBCA37-B85B-4C83-BE53-25283B257E2F

P433

Q33345317-887A68C9-628F-44DF-8689-B72446E169F6

P478

Q33345317-90544FED-E546-487E-847B-BF8C93F1CE71

P50

Q33345317-5FBEA0CB-3421-4089-B925-6419114AF235

P577

Q33345317-BB618478-4386-49AF-BB98-215E42E3BC4A

P698

Q33345317-96CB1798-65BF-4B47-82A9-80CD1F97C55D

P921

Q33345317-19393D95-C40A-4280-A2AA-717DE0D9FE9F

Q33345317-EA739F90-FD62-473B-B67E-12A4C74F4AF0

P356

JCO.2002.01.133

P1433

Journal of Clinical Oncology

P1476

Phase I trial of the proteasom ...... tory hematologic malignancies.

@en

P2093

Albert S Baldwin

http://www.w3.org/2001/XMLSchema#string

Beverly S Mitchell

http://www.w3.org/2001/XMLSchema#string

Christine S Pien

http://www.w3.org/2001/XMLSchema#string

Dixie-Lee Esseltine

http://www.w3.org/2001/XMLSchema#string

Jessica K Anderson

http://www.w3.org/2001/XMLSchema#string

Julian Adams

http://www.w3.org/2001/XMLSchema#string

Mary Jo Lehman

http://www.w3.org/2001/XMLSchema#string

Natalie D Depcik-Smith

http://www.w3.org/2001/XMLSchema#string

Owen A O'Connor

http://www.w3.org/2001/XMLSchema#string

Peter J Elliott

http://www.w3.org/2001/XMLSchema#string

P304

4420-4427

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2002.01.133

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Robert Z Orlowski

P577

2002-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12431963

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial